11/11
07:00 am
ncna
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
Medium
Report
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
9/25
04:01 pm
ncna
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
High
Report
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
9/3
10:12 am
ncna
NuCana plc (NASDAQ: NCNA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $150.00 to $25.00. They now have an "outperform" rating on the stock.
Medium
Report
NuCana plc (NASDAQ: NCNA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $150.00 to $25.00. They now have an "outperform" rating on the stock.
8/30
08:04 am
ncna
NuCana plc (NASDAQ: NCNA) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Medium
Report
NuCana plc (NASDAQ: NCNA) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
8/29
04:01 pm
ncna
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
High
Report
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study